Zhai, X., Jing, X., Li, J., Tian, Y., Xu, S., Wang, M., & Zhu, H. (2020). Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. Front Oncol.
Chicago Stili AlıntıZhai, Xiaoyang, Xuquan Jing, Ji Li, Yaru Tian, Shuhui Xu, Min Wang, ve Hui Zhu. "Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy As Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer." Front Oncol 2020.
MLA AlıntıZhai, Xiaoyang, et al. "Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy As Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer." Front Oncol 2020.